

ERRATUM

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy

Cristina Teixidó¹, Niki Karachaliou², Maria González-Cao², Daniela Morales-Espinosa², Rafael Rosell^{1,2,3}

¹Pangaea Biotech, Quirón Dexeus University Hospital, Barcelona 08028, Spain; ²Dr. Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona 08028, Spain; ³Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona 08916, Spain

In the published article¹, one error appeared on page 89.

Pembrolizumab has not yet received FDA approval for NSCLC patients. In October 2014 pembrolizumab received FDA breakthrough therapy designation for lung cancer treatment supported by data from a phase Ib trial in previously treated NSCLC patients².

The authors apologize for the errors and for any confusion it may have caused.

Acknowledgements

We are thankful to Dr. Dickran Kazandjian from FDA/Office

of Hematology and Oncology Products for pointing out this mistake.

References

1. Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. *Cancer Biol Med* 2015;12:87-95.
2. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med* 2015;372:2018-2028.

Correspondence to: Cristina Teixidó

E-mail: cteixido@pangaeabiotech.com

Received July 28, 2015; accepted July 29, 2015.

Available at www.cancerbiomed.org

Copyright © 2015 by Cancer Biology & Medicine

Cite this article as: Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R. Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy. *Cancer Biol Med* 2015;12:259. doi: 10.7497/j.issn.2095-3941.2015.0055